Small Cell Lung Cancer (SCLC) | Right Decisions

Right Decisions
Scottish Cancer Network: Clinical Management Pathways
Lung Cancer
Back
Systemic Anti-Cancer Therapy (SACT)
Small Cell Lung Cancer (SCLC)

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.

Patients with mixed SCLC/NSCLC pathology or those for concurrent chemoradiotherapy but with insufficient tissue sample for clear pathology, may be considered for carboplatin and etoposide.

Author	Nicola Steele (on behalf of SACT subgroup)	Reviewer	John Maclay
Date of creation/update	20/09/2023	Version number	1.0
Review Date	20/09/2026	Contact	nss.scottishcancernetwork@nhs.scot

The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.

Limited Stage SCLC

Extensive Stage SCLC